Notes

The Catalyst fund is currently researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The fund manager made a note on September 18, 2026, at 16:31:05 UTC. The manager reviewed SEC filings for IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on September 17, 2026. A discovery was made on September 9, 2026, at 13:12:14 UTC, where Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. The GIS conference was held on September 8, 2026, at 19:00 UTC, and the manager noted to check the replay. The manager also noted that GIS will have its earnings release on September 23, 2026, at 13:00 UTC, with a Q&A session, but the exact time of the first release is unknown. The manager will review the earnings release and verify the results. If GIS has stronger organic cash flow, the manager will record and validate the results, but if the cash flow is weaker or absent, the manager will reverify the results. The manager also noted that EAT will have its investor day on September 17, 2026, and its earnings call on October 28, 2026, but the exact time of the first release is unknown. The manager will review the earnings call and reverify the results. The manager made a decision to preserve the current position at 126, with an exit of 0.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 18, 2026, at 16:01:06 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, LOVE on September 10, 2026, and SFIX on July 28, 2026. The manager also reviewed the following RSS feeds: SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. Additionally, the manager checked the FDA website for updates on GRAL, which has a meeting scheduled for September 23, 2026. The manager noted that SEC filings may lag behind news and will review the following updates: new morning results on September 9 at 12:30, LOVE results on September 10 at 12:30, and SFIX results on September 24 at 12:30 after the September 23 AMC. The manager also noted that the GRAL panel on September 23 is not an approval. The manager will use a strong cash position to record and validate results, and a weak or early position to cash out and reverify. No automatic orders were placed.

The Catalyst Research fund has a size of 0 as of September 18, 2026, at 14:01:06 UTC. The fund manager reviewed the following news: Telix Pharma on September 17, 2026, at https://telixpharma.com/news-views/lets-go-lets-get-them/, Mission Produce on September 8, 2026, at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on September 8, 2026, at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, and Roivant on September 8, 2026, at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. The manager also reviewed financial reports from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Additionally, the manager checked news from Evolution Petroleum on September 15, 2026, and IPHA on September 17, 2026. The manager verified the integrity of data from KGF, ASKUL, IPHAnews, and SOBI. The manager decided to preserve monitors 165, 168, 167, 137, and 22, and to take no orders. The manager noted that IPHA had news on September 17, and Sobi had a receipt conditional on Q1 2028. The manager reminded to read originals and validate strong or new information, and to cash and reverify weak, absent, or erroneous information.

The Catalyst fund is currently researching IONS, MIRM, GIS, and EAT, with no current size, as of September 18, 2026, at 12:16:04 UTC. The fund has reviewed SEC filings for IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. On September 9, Barclays maintained an overweight rating on Ionis Pharmaceuticals, lowering its price target to $85. GIS had a conference on September 8, which has already passed, and will have earnings on September 23. The fund will review GIS's organic cash and guidance, and EAT's investor day was on September 17, with an earnings call scheduled for October 28. The fund will verify full pipelines and early news for these stocks, with no automatic trades or orders, as of September 18, 2026, at 12:16:06 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 18, 2026, at 12:01:06 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news releases from SAIL, KFY, and LOVE, which were published on September 9, 2026, September 9, 2026, and September 15, 2026, respectively. The manager also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The manager noted that SEC filings may lag behind news and that reviews will be done at 12:30 UTC on certain dates. The manager also stated that strong cash positions will be recorded and validated, while weak or early positions will be cashed out and reverified. No automatic orders were placed.

A fund manager reviewed notes for the Catalyst research fund, which has a size of 0 and compact receipts. The origins of the notes are in the PRE91108 archive, and the review was done on 2026-09-18T10:16:08.143845+00:00. The manager looked at various panels, including SEC filings for HITI and BFRI on 2026-09-14, a report from Dave & Buster's on September 14, 2026, and reviews of TSM and DATA.L. The manager also reviewed information about CAN, PLAY, and EGTX, including a conference on September 11 and a review on September 16. Additionally, the manager looked at information about BFRI's ITC and a lifted suspension on September 1. The review consisted of 11 panels, and the manager read the originals before taking action.

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the current time is 2026-09-18T09:46:05.769623+00:00. There are several news updates from various companies, including Telix Pharma on September 17, 2026, Mission Produce on September 8, 2026, ABM on September 8, 2026, and Roivant on September 8, 2026. Additionally, there are financial reports from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Evolution Petroleum also reported its fiscal fourth quarter and full year results on September 15, 2026. There are also updates from IPHA on September 17, 2026, and HTTP status codes from KGF, ASKUL, IPHAnews, and SOBI. The research notes that IPHA had an update on September 17, and there is a conditional receipt from Sobi for Q1-2028. The monitors 165, 168, 167, 137, and 22 should be preserved. The sources and dates are listed in the job script and journal. There are no orders.

The Catalyst fund is currently researching IONS, MIRM, GIS, and EAT, with no active trades. The fund size is 0. On September 18, 2026, at 08:16:05 UTC, the following notes were recorded. The Securities and Exchange Commission filings for IONS, MIRM, GIS, and EAT were reviewed on September 4, September 8, July 1, and September 17, respectively. A discovery note from Barclays on September 9 maintained an overweight rating on Ionis Pharmaceuticals and lowered the price target to $85. A conference review for GIS was scheduled for September 8 at 19:00 UTC. The earnings report for GIS is scheduled for September 23, with a Q&A session at 13:00 UTC. The fund will review the earnings report, but no automatic trades will be made. The baseline expectations for GIS are an EPS of $3.00-3.20 and organic growth of -1.5% to +0.5%. The fund also reviewed the investor day for EAT on September 17 and the upcoming earnings call on October 28. The fund will verify the full pipelines and early news for all stocks before making any decisions.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 18, 2026, at 08:01:06 UTC. The fund manager reviewed the following SEC filings: CHWY's 10-Q filing on September 9, 2026, ASO's 10-Q filing on September 9, 2026, LOVE's 10-Q filing on September 10, 2026, and SFIX's 8-K filing on July 28, 2026. The manager also reviewed the following RSS feeds: SAIL's announcement on September 9, 2026, KFY's announcement on September 9, 2026, and LOVE's announcement on September 15, 2026. Additionally, the manager checked the FDA website for updates on GRAL, which has a meeting scheduled for September 23, 2026. The manager noted that SEC filings may lag behind news and will review the following upcoming events: new morning results on September 9 at 12:30, LOVE's results on September 10 at 12:30, SFIX's results on September 24 at 12:30, and GRAL's panel meeting on September 23, which is not an approval meeting. The manager will preserve cash and validate records for strong positions, and reverify weak or early positions. No automatic orders were placed.

The fund is called Catalyst Research and it is for research purposes only. The fund size was checked at 0 UTC on 2026-09-18T05:46:04.126181+00:00. There are several news updates from various companies, including Telix Pharma on Thursday, September 17, 2026, which can be found at https://telixpharma.com/news-views/lets-go-lets-get-them/, Mission Produce on Tuesday, September 8, 2026, which can be found at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on Tuesday, September 8, 2026, which can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, and Roivant on Tuesday, September 8, 2026, which can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. Additionally, there are financial reports from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Evolution Petroleum also reported its fiscal fourth quarter and full year results on Tuesday, September 15, 2026, which can be found at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0. Furthermore, there are updates from IPHA on September 17, 2026, and a 6-K report from IPHA on September 17, 2026. The HTTP requests for KGF, ASKUL, IPHAnews, and SOBI all returned a status code of 200 with hashes 3313522fd352460d, e6f0d85c03a37ce6, ef3293fd5ff26cb3, and 7569409d160b2a08 respectively. The research is focused on IPHA as of September 17, and there is a conditional receipt from Sobi for Q1 2028. The monitors for 165, 168, 167, 137, and 22 are preserved. The sources and dates can be found in the job script and journal. There are no orders.

The fund, called Catalyst, is researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a current size of 0. The last update was on September 18, 2026, at 04:01:09 UTC. The fund manager has been reviewing SEC filings for these stocks, including IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. A news scan found the headline that Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85 on September 9. The GIS company had a conference on September 8, which has already passed, and the fund manager will review the replay. The fund manager is also waiting for the earnings report from GIS on September 23, which will include a Q&A session at 13:00 UTC. The fund manager has set a baseline for GIS's fiscal year 2027, expecting an EPS of $3.00-3.20 and organic growth of -1.5% to +0.5%. The fund manager is also monitoring EAT's investor day, which was held on September 17, and its upcoming earnings call on October 28. The fund manager has set rules for when to record or reverify the stocks' performance, but will not make any automatic trades. The fund manager will review the full pipelines and early news for these stocks.

The Catalyst fund is currently researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The fund's status was updated on September 18, 2026, at 04:01:09 UTC. The fund manager has been reviewing SEC filings for these stocks, including IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. A news scan found the headline that Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85 on September 9. GIS had a conference and review on September 8, and will have earnings and a Q&A session on September 23. The fund manager is monitoring GIS's organic cash and guidance, and will record and validate if it is stronger, or reverify if it is weaker or absent. The baseline for GIS's FY27 EPS is $3.00-3.20, with organic growth of -1.5 to +0.5% and savings of $750 million. EAT had an investor day on September 17 and will have an earnings call on October 28. The fund manager is monitoring EAT's organic cash and will record and validate if it is stronger, or reverify if it is weaker or absent. The fund is currently in research mode only and has not placed any orders.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 18, 2026, at 04:01:02 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The FDA calendar was also checked for GRAL, which has a panel meeting on September 23, 2026, but this is not an approval meeting. The manager noted that the SEC filings may lag behind news. The manager will review the following upcoming events: new morning results on September 9 at 12:30, LOVE results on September 10 at 12:30, and SFIX results on September 24 at 12:30, after the September 23 AMC. The manager will also monitor GRAL's panel meeting on September 23. The manager emphasized the importance of strong cash positions, which should be recorded and validated, while weak or early positions should be cashed out and reverified. No automatic orders were placed.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 18, 2026, at 04:01:02 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed the 8-K filing for SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The fund also checked the FDA website for information on GRAL, which had a meeting scheduled for September 23, 2026. The fund noted that SEC filings may lag behind news. It reviewed results on September 9 at 12:30 for new morning results, on September 10 at 12:30 for LOVE, and on September 24 at 12:30 for SFIX after the September 23 AMC. The fund also noted that the GRAL panel on September 23 was not for approval. The fund has a strong cash position, which needs to be recorded and validated, while weak or early positions need to be verified. No automatic orders were made.

A fund manager's notes for the Catalyst Research fund, which has a size of 0, were compacted on September 18, 2026, at 02:16:00.547241+00:00. The notes include a list of panels with previews of various events and announcements. Panel 0 shows the fund's details, including its size and a timestamp of 2026-09-18T02:15:56.003719+00:00. Panels 1 and 2 link to SEC filings for HITI and BFRI on September 14, 2026. Panel 3 mentions Dave & Buster's second-quarter 2026 report on September 14, 2026. Panel 4 refers to chosen reviews and data for TSM on September 10, 2026. Panel 5 notes new events for CAN on September 8, 2026, and PLAY on September 15, 2026. Panel 6 talks about improved organic cash and clinical evidence. Panels 7 and 8 provide information about EGTX, including a count of 48 and a latest update link. Panels 9 and 10 link to ITC information for BFRI, including a lifted suspension on September 1, 2026. These notes are a compilation of 11 panels with previews, and the originals should be read before taking any action.

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 2026-09-18T01:45:56.671498+00:00 UTC. There are several company updates: TLX on Thursday, September 17, 2026, has a news article at https://telixpharma.com/news-views/lets-go-lets-get-them/, AVO on Tuesday, September 8, 2026, has a news release at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on Tuesday, September 8, 2026, has a news release at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, and ROIV on Tuesday, September 8, 2026, has a news release at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. There are also several financial filings: UNFI on September 14, 2026, filed a 10-K at 0001020859-26-000025/unfi-20260801.htm, DRI on July 24, 2026, filed a 10-K at 0000940944-26-000025/dri-20260531.htm, PPIH on September 9, 2026, filed a 10-Q at 0001437749-26-029988/ppih20260731_10q.htm, MRK on August 7, 2026, filed a 10-Q at 0000310158-26-000212/mrk-20260630.htm, and WLTH on September 14, 2026, filed a 10-Q at 0001628280-26-061848/wlth-20260731.htm. Additionally, EPM on Tuesday, September 15, 2026, has a news release at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0, and IPHA on September 17, 2026, filed a 6-K at 0001628280-26-062360/a6kseptember172026.htm. The HTTP requests for KGF, ASKUL, IPHAnews, and SOBI were successful with hashes 3313522fd352460d, e6f0d85c03a37ce6, ef3293fd5ff26cb3, and 7569409d160b2a08, respectively. The research is strong for IPHA as of September 17, and there is a conditional receipt for Sobi for Q1 2028. The monitors for 165, 168, 167, and 137, and 22 are preserved. There are no orders and the sources and dates are in the job script and journal. The research is for strong and new information, and for weak or absent information, it is recommended to cash and reverify.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 18, 2026, at 00:01:05 UTC. The fund is monitoring the following stocks: IONS, MIRM, GIS, and EAT, as well as CAG. The fund manager has reviewed SEC filings for IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals and lowers its price target to $85 on September 9. GIS had a conference and review on September 8, which has already passed. The fund is waiting for General Mills' earnings release on September 23. The baseline expectations for GIS are an EPS of $3.00-3.20 for FY27, with organic growth of -1.5% to +0.5% and savings of $750 million. The fund manager has chosen to review EAT's investor day on September 17 and earnings call on October 28. The fund will verify full pipelines and early news for all stocks.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 18, 2026, at 00:01:00 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news releases from SAIL, KFY, and LOVE, which were published on September 9, 2026, and September 15, 2026. The manager also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The manager notes that SEC filings may lag behind news and will review results on the following schedule: September 9 at 12:30 for new morning results, September 10 at 12:30 for LOVE, and September 24 at 12:30 for SFIX after the September 23 AMC. The manager also notes that the GRAL panel on September 23 is not an approval meeting. The manager will use a strong cash position to record and validate results, and a weak or early position to cash out and reverify. No automatic orders were placed.

The fund is called Catalyst Research and it is for research purposes only. The size of the fund is 0 and the time is 2026-09-17T21:45:55.424445+00:00 UTC. There are several companies with updates: TLX on Thursday, 17 Sep 2026, has a news article at https://telixpharma.com/news-views/lets-go-lets-get-them/, AVO on Tuesday, 08 Sep 2026, has a news release at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on Tuesday, 08 Sep 2026, has a news release at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, and ROIV on Tuesday, 08 Sep 2026, has a news release at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. Additionally, there are financial reports for UNFI on 2026-09-14, DRI on 2026-07-24, PPIH on 2026-09-09, MRK on 2026-08-07, and WLTH on 2026-09-14. EPM has a news release on Tuesday, 15 Sep 2026, at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0. IPHA has a 6-K report on 2026-09-17. There are also HTTP200 hashes for KGF, ASKUL, IPHAnews, and SOBI. The research is focused on IPHA as of September 17, with a condition related to Sobi receipt and Q1-2028. The monitors for 165, 168, 167, 137, and 22 are preserved. There are no orders and the sources and dates are in the job script and journal. The research approach is to read originals and validate for strong and new information, and to cash and reverify for weak, absent, or error information.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 17, 2026, at 19:45:59 UTC. The fund is monitoring the following stocks: IONS, MIRM, GIS, EAT, and CAG. The fund manager has reviewed the SEC filings for IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on September 17, 2026. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals and lowers its price target to $85 on September 9, 2026. The fund manager also notes that GIS had a conference on September 8, 2026, and will have earnings on September 23, 2026. The baseline for GIS is an EPS of $3.00-3.20 for FY27, with organic growth of -1.5% to +0.5% and savings of $750m. The fund manager is monitoring EAT's investor day on September 17, 2026, and earnings call on October 28, 2026. The fund's strategy is to record and validate stronger organic cash growth and reverify weaker or absent growth. No automatic trades will be made. The fund manager will review the full pipelines and early news for these stocks.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 17, 2026, at 19:45:57 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news from SAIL, KFY, and LOVE, which were released on September 9, 2026, and September 15, 2026. The manager also checked the FDA website for information on GRAL, which has a panel meeting on September 23, 2026. The manager notes that SEC filings may lag behind news and will review results on September 9, 2026, at 12:30, September 10, 2026, at 12:30, and September 24, 2026, at 12:30. The manager also notes that the GRAL panel meeting on September 23, 2026, is not for approval. The manager has a strong cash position and will record and validate it, while weak or early positions will be cashed and reverified. There are no automatic orders.

A fund manager's notes were compiled on 2026-09-17T18:01:12.699231+00:00. The fund is called Catalyst Research, and it has a size of 0. The notes include compact receipts and origins from the PRE91108 archive. The notes are divided into 11 panels, each with a unique sha code, which is a type of digital fingerprint. The panels contain previews of various events and announcements, including SEC filings for HITI and BFRI on 2026-09-14, a report from Dave & Buster's on September 14, 2026, and a review of TSM on September 10. There are also mentions of EGTX, a company with 48 MFN counts, and its latest updates. Additionally, there are references to ITC and photodynamic therapy systems. The notes end with a statement to read the originals before taking action.

The fund in question is the Catalyst Research fund, which has a size of 0 as of September 17, 2026, at 17:31:07 UTC. There are several companies with recent news: Telix Pharma on September 17, 2026, at https://telixpharma.com/news-views/lets-go-lets-get-them/, Mission Produce on September 8, 2026, at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on September 8, 2026, at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, and Roivant on September 8, 2026, at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. Additionally, there are financial reports from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Evolution Petroleum also reported on September 15, 2026, at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0. Furthermore, there are filings from IPHA on September 17, 2026. The HTTP requests for KGF, ASKUL, IPHAnews, and SOBI all returned a status code of 200 with the respective hashes 3313522fd352460d, e6f0d85c03a37ce6, ef3293fd5ff26cb3, and 7569409d160b2a08. The research is for informational purposes only, and it is recommended to read the originals and validate the information, especially for strong or new data, while weak or absent data should be verified with cash and reverification. There is a note about IPHA on September 17 and a conditional receipt for Sobi in Q1 2028. The monitors 165, 168, 167, 137, and 22 should be preserved. The sources and dates can be found in the job script and journal, and there are no orders.

The Catalyst fund is currently researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The fund's status was updated on September 17, 2026, at 15:31:06 UTC. The fund manager has been reviewing SEC filings for these stocks, including IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals and lowers its price target to $85 on September 9. The GIS company had a conference on September 8, which has already passed. The fund is waiting for the GIS earnings report on September 23. The baseline expectations for GIS are an EPS of 3.00-3.20 and organic growth of -1.5 to +0.5%. The fund is also monitoring EAT, which had an investor day on September 17 and is scheduled to have an earnings call on October 28. The fund's decisions are based on the strength of the companies' organic cash flow, with stronger cash flow leading to record and independent validation, and weaker or absent cash flow leading to re-verification. The fund does not make automatic trades and requires manual review of the full pipeline and early news.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 17, 2026, at 15:31:04 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed the SFIX 8-K filing from July 28, 2026. Additionally, the manager looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The manager also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The manager noted that SEC filings may lag behind news and that reviews will be done at 12:30 UTC on September 9 for new morning results, September 10 for LOVE, and September 24 for SFIX after the September 23 AMC. The GRAL panel on September 23 is not for approval. The manager will use a strong cash position to record and validate, and a weak or early position to cash and reverify. No automatic orders were placed.